Document is current
Any future updates will be listed below
-
Authors
Liu, Hao https://orcid.org/0000-0001-9155-409X
Liu, Nan https://orcid.org/0009-0004-9557-6017
Zhou, Chen
Du, Ailing https://orcid.org/0000-0002-2219-5668
Kapadia, Mayank https://orcid.org/0009-0002-0209-7160
Tai, Phillip W L https://orcid.org/0000-0001-7409-8344
Barton, Erik
Gao, Guangping https://orcid.org/0000-0001-5916-3953
Wang, Dan https://orcid.org/0000-0001-9079-2360
-
Funding
Funding for this research was provided by:
HHS | National Institutes of Health (P01HL158506)
HHS | National Institutes of Health (R01NS076991-01,P01AI100263-01,P01HL131471-02,35 R01AI121135,UG3HL147367-01,R01HL097088)
HHS | National Institutes of Health (U19AI149646-01)
Cystic Fibrosis Foundation
Davis | Pfizer Foundation
- License Information
-
More Information
Article History
Received: 5 December 2024
Revised: 23 April 2025
Accepted: 25 April 2025
First Online: 16 May 2025
Disclosure and competing interests statement
: HL, GG, and DW are inventors of a patent application filed by the University of Massachusetts Chan Medical School concerning the work described in this study. EB was an employee of Pfizer Inc. when the study was conducted. GG is a scientific co-founder of Voyager Therapeutics, Adrenas Therapeutics and Aspa Therapeutics, and holds equity in these companies.
